2017年美国肿瘤学年会于美国当地时间6月2号到6号在芝加哥举行,作为全球最具影响力的肿瘤学盛会,本次会议吸引了近万名肿瘤临床医生和研究者。作为世界范围内最为常见的恶性肿瘤之一,结直肠癌相关的研究进展总能引起广泛关注。本次会议上,来自中国研究报告的数量和质量较往年又有新的突破。其中来自复旦大学附属肿瘤医院大肠外科蔡三军教授团队的研究“The FOXC1/FBP1 signaling axispromotes tumorigenicity by enhancingthe Warburg effect in colorectal cancer.”(摘要号e15123)作为在线发表,受到了参会者的关注。主要研究者复旦大学附属肿瘤医院李大卫副主任医师亲临大会现场,并为我们对该研究做了独家解读。
The FOXC1/FBP1 signaling axispromotes tumorigenicity by enhancing the Warburg effect in colorectal cancer.
Background:?Aberrant expression of Forkhead Box transcription factors plays vital roles in the oncogenesis and metastasis of many types of cancer. The purpose of this study is to elucidate the function of Forkhead Box C1(FOXC1) in colorectal cancer (CRC)malignancy maintenance.?Methods:?FOXC1 expression in CRC specimens was analyzed in the TCGA database and validated by immunohistochemistry using a tissue microarray (TMA). The effect of FOXC1 expression on cancer proliferation and glycolysis was assessed in cells by altering the expression of FOXC1?in vitro?and?in vivo. Mechanistic investigation was carried out by using cell and molecular biology approaches.?Results:?FOXC1 was found to be overexpressed in CRC specimens compared with that in the adjacent benign tissues. Univariate survival analyses of the TCGA and validated cohorts showed that high expression of FOXC1 was significantly correlated with shortened patient survival (P< 0.05). Attenuation of FOXC1 expression inhibited proliferation, clone formation and decreased glucose consumption and lactate production. By contrast, overexpression of FOXC1 had the opposite effect. Furthermore, increased FOXC1 expression downregulated the expression of a key glycolytic enzyme,fructose-1, 6-Bisphosphatase 1 (FBP1). Mechanistically, FOXC1 bound directly to the promoter regions of the FBP1 gene and negatively regulated its transcriptional activity. Aberrant FBP1 expression contributes to CRC tumorigenicity, and decreased FBP1 coupled with increased FOXC1 provided better prognostic information than FOXC1 did alone.?Conclusions:?The FOXC1/FBP1 axis induces cell proliferation, reprograms the metabolic process in CRC and provides potential prognostic predictors and therapeutic targets for patients with CRC
本研究是针对结直肠癌的驱动基因和分子机制进行的一项转化研究,研究者首次发现FOXC1是潜在的结直肠癌促癌基因和分子标志物,并有潜力成为肿瘤能量代谢的关键干预靶点。
FOXC1分子属于FOX家族成员,目前对其在肿瘤中发挥的功能机制尚不清楚。本课题研究者对FOXC1分子在结肠癌中的功能进行了深入探索,首次发现该分子在结肠癌病人样本中异常高表达,并显著影响患者生存预后,是潜在的分子标志物和预警分子。体内外实验证实FOXC1具有促进肿瘤恶性增殖作用,是潜在的促癌基因。更为重要的是,FOXC1可能通过调控肿瘤能量代谢影响其生物学作用。
近年来,能量代谢被认为是肿瘤最为重要的特征之一。肿瘤细胞的能量代谢与正常细胞具有显著差异。肿瘤细胞在有氧条件下仍以糖酵解而非氧化磷酸化提供能量,这种糖代谢途径的重编程被称为有氧糖酵解或Warburg效应。
有氧糖酵解是肿瘤能量代谢最为重要的方式,能够使肿瘤细胞快速有效获取能量满足分裂增殖,并在获取能量的过程中调控了线粒体损伤、代谢关键酶、基因组稳定性、血管生成等,产生的局部酸性环境又促进免疫逃逸、增加侵袭能力、维持肿瘤细胞干性和放化疗耐受性,深刻的影响了肿瘤多方面的生物学特征。因此,深入探索有氧糖酵解参与肿瘤发生发展的作用机制,具有重要的临床转化应用价值,近年来针对糖酵解的靶向药物在临床前期实验中也展现了良好的应用前景。
目前关于肿瘤有氧糖酵解的关键分子基础和确切机制尚未完全阐明。本研究首次发现,FOXC1可以通过在转录水平调控糖酵解关键酶FBP1促进肿瘤糖酵解,进而参与结直肠癌的恶性进展过程。研究者认为,FOXC1-FBP1信号通路的发现有助于促进肿瘤能量代谢的临床转化研究,未来如何针对筛选出的关键的调控分子靶点,进而研发高效低毒和特异性的代谢靶向药物是亟待解决的科学问题。